The atrophy of a specific region of the cerebral cortex is related to the appearance of apathy in Huntington’s patients, a neurodegenerative disease that affects motor and cognitive function. This is the conclusion of a study of the Bellvitge Biomedical Research Institute (IDIBELL) published in the Movement Disorders journal.
Hyperactivation of the RANK pathway plays a double function in breast cells: in the early stages of cancer, it activates senescence, which has a protective effect and delays the appearance of tumours
The date of the election to celebrate this anniversary coincides with the birth of nurse Florence Nightingale, a pioneer of modern nursing
May 12 – International Nursing Day Read More »
Research It is a rare disease that causes malformations in blood vessels. The study has discovered the implication of a protein in the development of the pathology.
Researchers identify a possible therapy against Rendu-Osler disease Read More »
The Ramón Areces Foundation has awarded Grants for Research in Life Sciences and Matter corresponding to its 20th edition. In intercellular dialogue and interactome area, Dr. Isabel Fabregat, head of the research group “TGF-beta and cancer” at IDIBELL, in collaboration with Drs. Aránzazu Sánchez and Blanca Herrera from the Complutense University of Madrid, have received one of the grants.
60% of Covid-19 inpatients develop neurological symptoms and 12% of post-Covid patients have neurological sequelae.
60% of Covid-19 patients develop neurological symptoms Read More »
This year within the framework of the Hospitalet Spring Festival, we enjoyed again in the Science Park.
Saturday was the day to enjoy and experiment in the Hospitalet science park Read More »
IDIBELL and the Virolai school, together in a new educational initiative of the Escolab program of the Barcelona City Council
We launch VacunAcció: a project to immunize against fake news Read More »
Bellvitge Biomedical Research Institute (IDIBELL) and Bellvitge University Hospital had launched a clinical study, along with the pharmaceutical company Takeda, to evaluate the efficacy and safety of Icatibant as a treatment against COVID-19.
The work of the Epidemiology of Bacterial Infections research group of IDIBELL and HUB indicates that the bacteria could achieve the resistance through the acquisition of mobile DNA fragments.
